Internal Medicine · Torrance, CA
NPI
1871675744
Since 2006
Specialty
Internal Medicine
Code 207R00000X
Group practices
0
Medicare group memberships
Hospitals
2
Hospital affiliations
3011 Artesia Blvd
Torrance, CA, 90504
Phone (310) 329-6395
Medicare paid, 2024
$206K
7,775 services
Medicare patients, 2024
102
Average age 76
Drug cost, 2024
$3.6M
7,231 prescriptions
Company payments, 2025
$3,366
From 21 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Zonglang Tsai was code 96372 (injection administration), 1,370 times for 93 patients. In total Zonglang Tsai billed 7,775 services in 35 codes, and Medicare paid $206K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-07-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 96372 Injection Administration | Office | 1,370 | 93 | $11.77 | $16K |
| J0897 Injection, denosumab, 1 mg | Office | 972 | 23 | $16.09 | $16K |
| 99214 Office E&M - Established | Office | 947 | 101 | $99.47 | $94K |
| 81002 Clinical Chemistry | Office | 821 | 98 | $3.41 | $2,800 |
| 82044 Clinical Chemistry | Office | 747 | 95 | $6.11 | $4,564 |
| 82570 Clinical Chemistry | Office | 743 | 95 | $5.08 | $3,774 |
| 82962 Clinical Chemistry | Office | 682 | 94 | $3.21 | $2,189 |
| 36415 Venipuncture Blood Collection | Office | 365 | 92 | $8.65 | $3,157 |
| 80061 Clinical Chemistry | Office | 199 | 85 | $13.12 | $2,611 |
| 95251 Test - Miscellaneous | Office | 116 | 47 | $28.79 | $3,340 |
| J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 100 | 27 | $0.96 | $96.22 |
| 99215 Office E&M - Established | Office | 98 | 66 | $147.26 | $14K |
| 95249 Test - Miscellaneous | Office | 88 | 28 | $58.17 | $5,119 |
| 90732 Vaccine Product | Office | 77 | 75 | $130.80 | $10K |
| G0009 Administration of pneumococcal vaccine | Office | 76 | 74 | $35.02 | $2,662 |
By year: 2022 $193K for 6,496 services; 2023 $206K for 8,355 services; 2024 $206K for 7,775 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 81002 Clinical Chemistry | 821 | 98 | $3.41 | $2,800 |
| 82044 Clinical Chemistry | 747 | 95 | $6.11 | $4,564 |
| 82570 Clinical Chemistry | 743 | 95 | $5.08 | $3,774 |
| 82962 Clinical Chemistry | 682 | 94 | $3.21 | $2,189 |
| 36415 Venipuncture Blood Collection | 365 | 92 | $8.65 | $3,157 |
| 80061 Clinical Chemistry | 199 | 85 | $13.12 | $2,611 |
| 83880 Clinical Chemistry | 34 | 15 | $35.94 | $1,222 |
Medicare prescription drug claims, 2024
In 2024, the drug Zonglang Tsai prescribed most often to Medicare patients was Kerendia (Finerenone), with 375 prescriptions and refills. In total Zonglang Tsai wrote 7,231 Medicare prescriptions that cost $3.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Kerendia Finerenone | 375 | 456 | 47 | $287K |
| Ezetimibe Generic | 350 | 607 | 68 | $9,167 |
| Jardiance Empagliflozin | 322 | 482 | 57 | $264K |
| Praluent Pen Alirocumab | 297 | 340 | 43 | $166K |
| Afrezza Insulin Regular, Human | 265 | 275 | 39 | $349K |
| Acarbose Generic | 252 | 346 | 45 | $11K |
| Vascepa Icosapent Ethyl | 232 | 304 | 43 | $112K |
| Repatha Sureclick Evolocumab | 182 | 213 | 28 | $116K |
| Amlodipine Besylate Generic | 168 | 245 | 29 | $605 |
| Tamsulosin Hcl Generic | 156 | 260 | 33 | $1,553 |
| Icosapent Ethyl Generic | 143 | 187 | 34 | $27K |
| Dexlansoprazole Dr Dexlansoprazole | 139 | 178 | 27 | $28K |
| Pantoprazole Sodium Generic | 112 | 163 | 22 | $781 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 105 | 105 | 15 | $1,666 |
| Ozempic Semaglutide | 105 | 117 | 17 | $104K |
Brand drugs: 3,228 claims; generic drugs: 3,889 claims; opioid claims: 118.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Zonglang Tsai $3,366 ($3,366 in general payments such as food, travel and fees) from 21 companies. The largest payer was Amgen Inc. with $617.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 32 | $617 |
| Abbvie Inc. ABBV | 22 | $496 |
| Alkermes, Inc. ALKS | 16 | $393 |
| Corcept Therapeutics CORT | 13 | $315 |
| AstraZeneca Pharmaceuticals LP AZN | 7 | $240 |
| Paratek Pharmaceuticals, Inc. | 18 | $216 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) JNJ | 6 | $173 |
| Sanofi-Aventis U.S. LLC SNY | 1 | $150 |
| Merck Sharp & Dohme LLC MRK | 4 | $112 |
| Sumitomo Pharma America, Inc. 4506.T | 4 | $109 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.